当前位置:首页>产品中心>单抗/多抗>Anti-Human HDGFL2 Recombinant Nanobody |抗人HDGFL2纳米抗体(靶标:人HDGF样蛋白2)

Anti-Human HDGFL2 Recombinant Nanobody |抗人HDGFL2纳米抗体(靶标:人HDGF样蛋白2)

  • 货号:RB9THA200013
  • 价格:面议
  • 点击:210

产品介绍

产品参数

形态Liquid
宿主种属Alpaca
克隆性Monoclonal
抗体亚型VHH-His
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
内毒素水平Please contact with the lab for this information.
应用ELISA
种属反应性Homo sapiens (Human)
靶标HDGF-2, HDGF-related protein 2, HDGF2, HDGFL2, HDGFRP2, HRP-2, HRP2, Hepatoma-derived growth factor 2, Hepatoma-derived growth factor-related protein 2
储存缓冲液0.01M PBS pH 7.4
稳定性和储存Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
重构方法Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
登录号Q7Z4V5
背景信息

Hepatoma-derived growth factor-related protein 2 (HDGFL2) is a ~74 kDa protein. Acts as an epigenetic regulator of myogenesis in cooperation with DPF3a (isoform 2 of DPF3/BAF45C). Associates with the BAF complex via its interaction with DPF3a and HDGFL2-DPF3a activate myogenic genes by increasing chromatin accessibility through recruitment of SMARCA4/BRG1/BAF190A (ATPase subunit of the BAF complex) to myogenic gene promoters. Promotes the repair of DNA double-strand breaks (DSBs) through the homologous recombination pathway by facilitating the recruitment of the DNA endonuclease RBBP8 to the DSBs. Preferentially binds to chromatin regions marked by H3K9me3, H3K27me3 and H3K36me2. Involved in cellular growth control, through the regulation of cyclin D1 expression.

1. Zhu, X. et al. (2020) Nucleic acids research 48, 6563-6582. PMID: 32459350
2. Baude, A. et al. (2016) Nucleic acids research 44, 2214-26. PMID: 26721387
3. Gao, K. et al. (2015) Biochemical and biophysical research communications 458, 849-55. PMID: 25689719
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 425
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 537
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 377
Anti-Daclizumab Neutralizing Recombinant Antibody |抗达克珠单抗中和重组抗体(靶标:达克珠单抗中和抗体) 510
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 389
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 480
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 237
Anti-Atibuclimab Neutralizing Recombinant Antibody |抗阿替布利单抗中和重组抗体(靶标:阿替布利单抗中和抗体) 299
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 254
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 455
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 569
Anti-Secukinumab Neutralizing Recombinant Antibody |抗司库奇尤单抗中和重组抗体(靶标:司库奇尤单抗中和抗体) 386
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 380
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 573
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 594
Anti-Enfortumab Neutralizing Recombinant Antibody |抗恩福妥单抗中和重组抗体(靶标:恩福妥单抗中和抗体) 422
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 254
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 573
Anti-Certolizumab Non-Neutralizing Recombinant Antibody |抗赛妥珠单抗非中和重组抗体(靶标:赛妥珠单抗非中和抗体) 465
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 271
总计 33037 个记录,共 1652 页,当前第 1650 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00